Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2019 16:52 ET
|
Radius Health Inc.
WALTHAM, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors...
Radius Health to Present at Jefferies 2019 Global Healthcare Conference in London
November 15, 2019 16:15 ET
|
Radius Health Inc.
WALTHAM, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the...
Radius Health Announces Third Quarter 2019 Results and Corporate Update
November 05, 2019 16:05 ET
|
Radius Health Inc.
TYMLOS U.S. net sales grew to $47M and is capturing half of anabolic new patient starts1 Guidance for FY 2019 sales increased to $168-$172M (vs. $165-$170M prior) and year-end cash, cash equivalents...
Radius Health to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 5, 2019
October 23, 2019 17:37 ET
|
Radius Health Inc.
WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019. The Company...
Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting
September 13, 2019 18:03 ET
|
Radius Health Inc.
WALTHAM, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced it will present five posters, including results from a real-world study on patient experience,...
Radius Health to Participate in the Citi 14th Annual Biotech Conference and Morgan Stanley 17th Annual Global Healthcare Conference in September
September 03, 2019 09:00 ET
|
Radius Health Inc.
WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2019. Radius Health management will...
Radius Health Announces Second Quarter 2019 Operating Results
August 07, 2019 16:01 ET
|
Radius Health Inc.
TYMLOS® U.S. net sales were $41.0 million in the second quarter of 2019, an 81% growth over the second quarter of 2018. TYMLOS continued increasing its share of the U.S. anabolic osteoporosis...
Radius Health Initiates Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture
August 05, 2019 16:00 ET
|
Radius Health Inc.
Abaloparatide-Patch patient assessment study results demonstrated high patient acceptability and self-administration accuracy over a 29-day periodLevels of PINP, a biomarker for bone formation, after...
Radius Health to Announce Second Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, August 7, 2019
July 23, 2019 09:00 ET
|
Radius Health Inc.
WALTHAM, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter 2019 financial results on Wednesday, August 7th, 2019. The...
Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2019 16:52 ET
|
Radius Health Inc.
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors...